A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

NCT03882762 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetic

Interventions

DRUG: Cebranopadol 200 μg tablet

Sponsor

Tris Pharma, Inc.

Collaborators

[object Object]